Saltzman Edward C 4

What Happened
Edward C. Saltzman, a director of Nurix Therapeutics, was granted a derivative award representing 31,250 shares on 2026-05-15. The reported transaction shows an acquisition of 31,250 shares at $0.00 (derivative), meaning this is an award/option-type grant rather than an immediate purchase of stock and no cash changed hands at grant.

Key Details

• Transaction date: 2026-05-15. Report filed same date (timely).
• Transaction type: Award/Grant of a derivative security (code A).
• Shares/units granted: 31,250 (reported at $0.00).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The award vests 100% on the earlier of (a) the next annual meeting of stockholders or (b) May 15, 2027, subject to Saltzman’s continued service on the vesting date.
• No exercise price, immediate sale, tax withholding, or 10b5-1 plan noted in the excerpt.

Context
This filing reflects a future-looking equity award (an option/derivative that vests later) rather than an immediate transfer of marketable shares. Such grants are common for directors as part of compensation and do not by themselves indicate a buy or sell signal; the economic value will depend on vesting and any exercise price or later sales.